Mark Litzow Profile
Mark Litzow

@MRLitzow

Followers
609
Following
4
Media
4
Statuses
27

I am a hematologist, professor of medicine and specialist in blood and marrow transplantation and in the treatment of acute and chronic leukemia

Mayo Clinic
Joined November 2012
Don't wanna be here? Send us removal request.
@MRLitzow
Mark Litzow
2 years
Join us at Acute & Chronic Leukemias: Practical Applications 2023 on Oct. 6-7 in Orlando, FL (or via livestream). This year’s conference features interactive case presentations with panels of experts weighing in on pivotal treatment issues. Register here:
0
2
8
@ESHaematology
ESH (Haematology)
3 years
📣 #ESHALL2023 STARTS IN 1 MONTH! Don’t delay! REGISTER NOW & join us on May 19-21, 2023 in Berlin 🇩🇪 ➡ https://t.co/0alWOKoVPh 3rd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA Chairs: @CoolsJn, @DombretHerve, @AdeleKFielding, @MRLitzow #ESHCONFERENCES #LEUsm
0
3
3
@MRLitzow
Mark Litzow
3 years
Please consider attending the 3rd Translational Research Conference on ALL in Berlin May 19-21, 2023. Great line up of translational and clinical talks at #ESHALL2023.
0
1
8
@MRLitzow
Mark Litzow
5 years
Condolences to President Trump and his family on the death of his brother, Robert, yesterday.
0
0
3
@MRLitzow
Mark Litzow
5 years
Randomizes trial reported at ASCO shows benefit of early integrated palliative care for patients undergoing induction chemotherapy for AML! https://t.co/a2sVZYA9ik
0
5
23
@MRLitzow
Mark Litzow
6 years
via @NYTimes, interesting article on unreliability of many antibody tests for SARS-COV-2.
Tweet card summary image
nytimes.com
A team of scientists worked around the clock to evaluate 14 antibody tests. A few worked as advertised. Most did not.
0
0
1
@MRLitzow
Mark Litzow
6 years
A lay statement from the New York Times on the unique pulmonary physiology of COVID-19.
0
0
1
@MRLitzow
Mark Litzow
6 years
0
0
0
@MRLitzow
Mark Litzow
6 years
Global Concert to celebrate coronavirus workers finale song
1
0
2
@MRLitzow
Mark Litzow
7 years
Yes, correct, it was R-ibrutinib. Thanks for clarifying!
@RenoHemonc
Santhosh Ambika
7 years
@MRLitzow @ASH_hematology Wasn't it R-Ibrutinib > FCR?
0
0
2
@MRLitzow
Mark Litzow
7 years
Big year for CLL at ASH 2018! Alliance-led NCTN trial shows Ibrutinib superior to BR in elderly (Plenary session) and ECOG-ACRIN-led NCTN trial shows superiority of Ibrutinib over FCR (LBA Session). And Michael Hallek is giving Ham Wasserman lecture on CLL. @ASH_hematology
2
22
61
@MRLitzow
Mark Litzow
7 years
Happy Thanksgiving from Bowen Island, BC!
0
0
6
@MRLitzow
Mark Litzow
9 years
#MayoFacDev at the Twitter class with one of my first Tweets @erhall1
2
0
2
@MRLitzow
Mark Litzow
9 years
@akeithstewart Keith, I joke that I became a hematologist because we don't have to deal with surgeons much! Mark @MRLitzow
0
0
0
@MRLitzow
Mark Litzow
10 years
0
0
0
@MRLitzow
Mark Litzow
11 years
Great results in AYA results presented by Wendy Stock this morning! http://t.co/suJFFTff3f
0
0
1